Research programme: cancer and infectious disease therapeutics - Novartis/ University of California
Latest Information Update: 28 Oct 2021
Price :
$50 *
At a glance
- Originator Novartis; University of California at Berkeley
- Class Anti-infectives; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2021 No recent reports of development identified for research development in Infections in USA
- 28 Sep 2017 Early research in Cancer in USA (unspecified route)